ETFdb Logo
ETFdb Logo
  • ETF Database
  • Channels
    • Active ETF
    • Alternatives
    • Beyond Basic Beta
    • China Insights
    • Climate Insights
    • Commodities
    • Core Strategies
    • Crypto
    • Disruptive Technology
    • Dividend
    • Dual Impact
    • Emerging Markets
    • Energy Infrastructure
    • ESG
    • ETF Building Blocks
    • ETF Education
    • ETF Strategist
    • Fixed Income
    • Free Cash Flow
    • Future ETFs
    • Global Diversification
    • Gold/Silver/Critical Minerals
    • Innovative ETFs
    • Institutional Income Strategies
    • Leveraged & Inverse
    • Managed Futures
    • Market Insights
    • Megatrends
    • Modern Alpha
    • Multi-Asset
    • Night Effect
    • Portfolio Strategies
    • Retirement Income
    • Richard Bernstein Advisors
    • Tax Efficient Income
    • Thematic Investing
    • Volatility Resource
  • Tools
    • ETF Screener
    • ETF Country Exposure Tool
    • ETF Sector Tracker Tool
    • ETF Database Categories
    • Head-To-Head ETF Comparison Tool
    • ETF Stock Exposure Tool
    • ETF Issuer Fund Flows
    • Indexes
    • Mutual Fund To ETF Converter
    • ETF Data for Journalists
    • ETF Nerds
  • Research
    • First Bitcoin ETF
    • ETF Education
    • Equity Investing
    • Dividend ETFs
    • Leveraged ETFs
    • Inverse ETFs
    • Index Education
    • Index Insights
    • Top ETF Sectors
    • Top ETF Issuers
    • Top ETF Industries
  • Webcasts
  • Themes
    • AI ETFs
    • Blockchain ETFs
    • See all Thematic Investing ETF themes
    • ESG Investing
    • Marijuana ETFs
  • Multimedia
    • ETF 360 Video Series
    • ETF Trends on Videos
    • ETF Trends on Podcasts
    • ETF Prime Podcast
  • Company
    • About Us
    • Swag Store
  • PRO
    • Pro Content
    • Pro Tools
    • Advanced
    • FAQ
    • Pricing
    • Free Sign Up
    • Login
  1. Beyond Basic Beta Channel
  2. Pharma ETF Rebound Could Be Fueled by Growth, Innovation
Beyond Basic Beta Channel
Share

Pharma ETF Rebound Could Be Fueled by Growth, Innovation

Tom LydonDec 21, 2022
2022-12-21

For much of 2020 and 2021, the pharmaceutical stock investment thesis revolved around development and disbursement of coronavirus vaccines.

While that made for an obvious catalyst, and a rewarding one at that, the effects of the COVID-19 vaccine status as an accelerant for pharma equities waned this year. Fortunately, exchange traded funds such as the VanEck Vectors Pharmaceutical ETF (PPH A-) feature rosters that are chock full of quality companies with multiple traits that could power 2023 rebounds.

Looking ahead, some market observers are forecasting that pharma equities can rally in a post-COVID healthcare investment landscape on the back of factors such as innovation, expansion of generic offerings, and consumer health products.

“This follows the simplification of business models established by Pfizer and GSK that focused on core innovation. We expect a similar strategic refocus could be implemented at Novartis, which has already expressed its desire to separate its generic and innovative pharma businesses, and streamline its research efforts. We also expect Sanofi to continue its repositioning towards specialty pharma over the medium term,” noted Fitch Ratings.

Pfizer (NYSE:PFE), Novartis (NYSE:NVS), and Sanofi (NYSE:SNY) combine for over 14% of the PPH portfolio. GlaxoSmithKline (GSK) isn’t among the ETF’s 25 holdings.

Another factor pharma investors will want to stay abreast of next year is increased mergers and acquisitions activity, which is widely expected following a couple of years of lethargy on that front. With many large-cap pharma names, including some PPH components, facing patent cliffs in the coming years and rising generic competition, it makes sense for some to put cash to work by acquiring smaller rivals with robust product pipelines.

“We also expect active portfolio management within companies’ divisions, including targeted M&A and partnering opportunities, but also divestments of tail-end drugs and brands to free up resources for innovation. In our view this will continue to offer significant investment opportunities in the mid-cap pharma market, attracting significant private equity capital, particularly in consolidating European market,” according to Fitch.

The bulk of PPH’s member firms carry credit ratings that are well into investment-grade territory. More importantly, the firms have the capital to not only service debt obligations, but fund and grow dividends — an important factor for long-term investors.

“Most Fitch-rated global pharma companies enter 2023 with comfortable rating headroom. This not only reflects benefits for issuers involved in the pandemic response (including treatments and vaccines), but also the business model specialisation, which has led to a simplification of businesses, often raising disposal proceeds and increasing financial flexibility,” concludes Fitch.

For more news, information, and analysis, visit the Beyond Basic Beta Channel.

Loading Articles...
Help & Info
  • Contact Us
Tools
  • ETF Screener
  • ETF Analyzer
  • Mutual Fund to ETF Converter
  • Head-To-Head ETF Comparison
  • ETF Country Exposure Tool
  • ETF Stock Exposure Tool
  • ETF Performance Visualizer
  • ETF Database Model Portfolios
  • ETF Database Realtime Ratings
  • ETF Database Pro
More Tools
  • ETF Launch Center
  • Financial Advisor & RIA Center
  • ETF Database RSS Feed
Explore ETFs
  • ETF News
  • ETF Picks of the Month
  • ETF Category Reports
  • Premium Articles
  • Alphabetical Listing of ETFs
  • Best ETFs
  • Browse ETFs by ETF Database Category
  • Browse ETFs by Index
  • Browse ETFs by Issuer
  • Compare ETFs
Legal
  • Terms of Use and Privacy Policy
  • © 2023 VettaFi LLC. All rights reserved.
Follow ETF Database
Follow ETF Database

Advertisement

Is Your Portfolio Positioned With Enough Global Exposure?

ETF Education Channel

How to Allocate Commodities in Portfolios

Tom LydonApr 26, 2022
2022-04-26

A long-running debate in asset allocation circles is how much of a portfolio an investor should...

Core Strategies Channel

Why ETFs Experience Limit Up/Down Protections

Karrie GordonMay 13, 2022
2022-05-13

In a digital age where information moves in milliseconds and millions of participants can transact...

}
X